Glycopeptide Utilizing Patents (Class 514/20.9)
-
Publication number: 20120219573Abstract: The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.Type: ApplicationFiled: September 3, 2010Publication date: August 30, 2012Inventors: Patrick Baumhof, Thomas Schlake
-
Publication number: 20120219504Abstract: The present invention relates to a complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, to the use thereof as a drug delivery carrier for manufacturing medicines, and to a vaccine composition and a contrast agent comprising the composite. The protein comprising zinc oxide-binding peptides significantly improves the in vivo availability of zinc oxide-binding peptides, and therefore the complex of the present invention can be used not only as a drug delivery carrier for in vivo drug delivery or intracellular drug delivery, but also for in vivo imaging or cell imaging. The complex can be used for producing separating agents for effectively separating biological materials, therapeutic agents for hyperthermia, etc., contrast agents for MRI, and beads applicable to biosensors.Type: ApplicationFiled: November 3, 2010Publication date: August 30, 2012Applicants: SNU R&DB FOUNDATION, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventors: Nam-Hyuk Cho, Taek-Chin Cheong, Seung-Yong Seong, Ji Hyun Min, Jun Hua Wu, Young-Keun Kim
-
Publication number: 20120214747Abstract: The present invention relates recombinant human ?1-antitrypsin (rhAAT) comprising N-linked glycans, wherein at least 10% of said N-linked glycans are tetra-antennary glycans; and the degree of capping with sialic acid on said N-linked glycans (Z/A) is at least 50%. The invention further relates to rhAAT for use as a medicament, in particular for use in the prevention and/or treatment of a disease associated with AAT deficiency, and/or a disease involving neutrophil-mediated tissue damage.Type: ApplicationFiled: April 20, 2010Publication date: August 23, 2012Inventors: Elisabeth C.M. Brinkman, Cornelis E. Hack, Ingrid Van Den Nieuwenhof
-
Publication number: 20120208771Abstract: Synthetic cholesterylamine-linkers can include derivatives of cholesterol, cholesteryl, or sitosteryl coupled through the linker to an agent for delivery into cells. The cholesterylamines are thought to mimic cholesterol in the capacity and mechanism for enhanced entry into cells. The configuration of the cholesterylamine-linker that is thought to provide for enhanced entry into cells includes a cholesterylamine that is coupled to a linker from the amine, and which linker includes a negative charge at a spatial distance from the amine of the cholesterylamine.Type: ApplicationFiled: August 12, 2010Publication date: August 16, 2012Applicants: THE PENN STATE RESEARCH FOUNDATION, UNIVERSITY OF KANSASInventor: Blake R. Peterson
-
Publication number: 20120207819Abstract: The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked ?-gal epitopes for induction of recruitment of macrophages localized within or surrounding damaged tissue. The recruited macrophages recruit stem cells and promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, heart muscle, skeletal muscle, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues.Type: ApplicationFiled: August 17, 2010Publication date: August 16, 2012Applicant: University of MassachusettsInventor: Uri Galili
-
Publication number: 20120207720Abstract: In various embodiments, the present disclosure provides a method of treating a subject using laminin or a composition that includes laminin. In one embodiment, the method is used to enhance muscle regeneration, maintenance, or repair in a subject. In another embodiment, the method is used to promote wound healing. The method, in yet another embodiment, is used to prevent or reduce muscle damage or injury. In specific implementations of these methods, the laminin or composition that includes laminin is administered in a therapeutically effective amount. In some implementations, the laminin is a complete laminin protein. In other implementations, the laminin is a laminin fragment, a laminin derivative, or a laminin analogue.Type: ApplicationFiled: April 20, 2012Publication date: August 16, 2012Inventors: Dean J. Burkin, Jachinta E. Rooney
-
Publication number: 20120207705Abstract: A process for preparing a conditioned cell culture medium is provided. The process comprises a) culturing eukaryotic cells in a growth medium having a composition effective to support cell growth; b) separating the cultured cells from the growth medium; and c) maintaining the cultured cells in a basal medium having a composition suitable to maintain cell viability, but not to support substantial cell growth. The cells are preferably dermal sheath, dermal papilla or dermal fibroblast cells. The compositions are useful as pharmaceutical compositions, especially for wound healing.Type: ApplicationFiled: September 16, 2010Publication date: August 16, 2012Inventor: Bhupendra Vallabh Kara
-
Publication number: 20120202753Abstract: A method of inhibiting inflammation in a subject comprising the administration of milk oligosaccharides or glycoconjugates containing milk oligosaccharides is disclosed.Type: ApplicationFiled: July 2, 2010Publication date: August 9, 2012Applicants: Instituto Nacional de Ciencias Medicas Y Nutricion, The General Hospital Corporation d/b/a Massachusetts General Hospital, (CCHMC)Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
-
Publication number: 20120201857Abstract: The present invention provides a method and product for transdermal delivery of therapeutics, including neurotoxins and methods for use thereof. The method and system comprises pharmaceutical compositions for facilitating transdermal delivery of therapeutics without pain by absorption and more particularly a series of pharmaceutical formulations for topical administration of neurotoxins to humans, including a neurotoxin, such as a botulinum toxin, and absorption enhancing agents that facilitate absorption of the neurotoxin through the skin of the patient and do not eliminate the bioactivity associated with the neurotoxin. The pharmaceutical compositions are topically applied on a patient, and are generally in a cream or gel form.Type: ApplicationFiled: March 17, 2010Publication date: August 9, 2012Inventor: Pankaj Modi
-
Publication number: 20120202752Abstract: Embodiments of the present invention are directed generally to antisense compounds and compositions for the treatment of muscular dystrophy, and in particular, Duchenne muscular dystrophy (DMD). In one embodiment, the invention is directed to antisense oligonucleotide molecules, pharmaceutical compositions and formulations comprising antisense oligonucleotide molecules, and methods of treating muscular dystrophy related diseases and disorders wherein the antisense oligonucleotide molecules comprises a base sequence selected from the group consisting of SEQ ID NO: 5-8, 10, 12, 14, 16, 24, 27, 28, 34, 35, 37, 40, 42, 44-46, 79, 97, 100, 101, and 116, and combinations thereof.Type: ApplicationFiled: February 8, 2012Publication date: August 9, 2012Applicant: The Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical CenterInventor: Qi Long Lu
-
Publication number: 20120201753Abstract: Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating tissue, wound sites, and tumors in animals.Type: ApplicationFiled: April 19, 2012Publication date: August 9, 2012Inventors: Erkki Ruoslahti, Tero Jarvinen
-
Publication number: 20120195967Abstract: The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter its conformation. The change in conformation increases its crytallinity or liquid crystallinity, thus controlling the release of a therapeutic agent from the formulation. This can be accomplished as single material carriers or in a layer-by-layer fashion to load different therapeutic agents or different concentrations of these agents in each layer.Type: ApplicationFiled: April 10, 2012Publication date: August 2, 2012Applicants: Eidgenossisches Technische Hochschule (The Swiss Federal Institute of Technology), TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Lorenz Meinel
-
Publication number: 20120196810Abstract: There are provided an anionic polymer, a polyion complex, and a ternary polymer composite, each of which is stable in a biological environment and is capable of realizing small RNA delivery without causing any undesired immune response. An anionic polymer according to an embodiment of the invention includes: a main chain which includes repeating units having carboxyl groups; and a side chain which is linked with part of the carboxyl groups in the main chain and is represented by the following formula: -A-B—X where : A represents a residue having one or more aminoethyl bonds; B represents an in vivo cleavable bond; and X represents a small RNA. A polyion complex according to an embodiment of the invention includes the anionic polymer as described above and a cationic polymer. A ternary polymer composite according to an embodiment of the invention includes the polyion complex as described above and a charge conversional polymer.Type: ApplicationFiled: July 23, 2010Publication date: August 2, 2012Applicant: THE UNIVERSITY OF TOKYOInventors: Kazunori Kataoka, Atsushi Ishii, Hiroyasu Takemoto, Masataka Nakanishi, Nobuhiro Nishiyama, Kanjiro Miyata
-
Patent number: 8232252Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.Type: GrantFiled: July 3, 2008Date of Patent: July 31, 2012Assignee: Genetics Institute, LLCInventors: Glenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw
-
Publication number: 20120189537Abstract: Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating hyperproliferative diseases, inflammatory diseases and viral and bacterial infections and inducing apoptosis in cancer cells.Type: ApplicationFiled: November 22, 2011Publication date: July 26, 2012Inventor: Krishna Menon
-
Publication number: 20120189597Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including one or more exogenous nucleotides.Type: ApplicationFiled: August 9, 2010Publication date: July 26, 2012Applicant: NESTEC S.A.Inventors: Norman Alan Greenberg, Douglas Richard Bolster
-
Publication number: 20120183538Abstract: The invention provides SPARC antisense oligonucleotides and methods of their use in proliferative diseases such as cancer and hepatic fibrosis.Type: ApplicationFiled: July 9, 2010Publication date: July 19, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Vuong Trieu, Larn Hwang, Neil Desai
-
Publication number: 20120183564Abstract: The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent”), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.Type: ApplicationFiled: September 16, 2010Publication date: July 19, 2012Inventor: Bruce A. SULLENGER
-
Publication number: 20120184497Abstract: The invention provides dosage forms and compositions for treatment of bacterial infections. The dosage form may include a sterile, stable, particle-free dalbavancin powder suitable for reconstitution with a pharmaceutically acceptable vehicle. The dosage form may include a dalbavancin factor B0 and at least one additional dalbavancin factor among A0, A1, B1, B2, C0, and C1. The dosage form may also include a stabilizing substance.Type: ApplicationFiled: March 23, 2012Publication date: July 19, 2012Inventors: Martin STOGNIEW, Luigi COLOMBO, Romeo CIABATTI
-
Publication number: 20120177726Abstract: The present invention relates to medical use of liposomes, more particular the first medical use of sPLA2 hydrolysable liposomes. Such liposomes may be used for targeted delivery of therapeutic agents to cancerous tissue and in such embodiments; the therapeutic agents are typically small molecule antitumor agents. Other aspects of the inventions relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastrointestinal toxicity of a therapeutic agent. Yet another aspect of the present invention relate to methods of prolonging the therapeutic effect of a therapeutic agent.Type: ApplicationFiled: September 16, 2010Publication date: July 12, 2012Applicant: Bio-Bedst ApSInventors: Morten Just Petersen, Fredrik Melander, Andres Falk Vikbjerg, Sune Allan Petersonm, Mognes Winkel Madsen
-
Publication number: 20120177659Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 29, 2011Publication date: July 12, 2012Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Candy N. LEE, Tao HE, Mehdi MESRI, Elizabeth G. JOSELOFF, Paul MOORE, Katherine MCKINNON, Bruno DOMON
-
Publication number: 20120177719Abstract: A device including a body (12) including fibers without oxidized cellulose. The body (12) also includes fibers containing oxidized cellulose.Type: ApplicationFiled: December 9, 2011Publication date: July 12, 2012Applicant: Perouse MedicalInventors: Vithuy Dao, Robert Michelot, Eric Perouse
-
Publication number: 20120177579Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: ApplicationFiled: December 30, 2011Publication date: July 12, 2012Applicant: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Publication number: 20120178702Abstract: Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.Type: ApplicationFiled: July 22, 2011Publication date: July 12, 2012Applicant: University of PittsburghInventors: Leaf HUANG, Xiang Gao, Frank L. Sorgi
-
Publication number: 20120171206Abstract: Provided herein are methods and compositions, including pharmaceutical compositions, for stimulating liver regeneration after partial hepatectomy, massive liver resection and toxic injury, or following liver transplantation, including small-for-size liver transplantation, by inhibiting activation of complement.Type: ApplicationFiled: July 2, 2010Publication date: July 5, 2012Inventors: Stephen Tomlinson, Songqing He, Carl Atkinson
-
Publication number: 20120172289Abstract: The present invention relates to a compound of formula (I) and compositions thereof, methods of their production as well as methods for treating bacterial infection.Type: ApplicationFiled: December 28, 2011Publication date: July 5, 2012Applicant: NANYANG TECHNOLOGICAL UNIVERSITYInventors: Bengang Xing, Tingting Jiang, Roushen Liew
-
Publication number: 20120164145Abstract: Helicobacter pylori, one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a ?1,6-glucan-containing Helicobacter pylori compound comprising the structure of Formula (I): wherein R is a ?-DDHep-3-?-L-Fuc-3-?-GlcNAc trisaccharide substituted with an ?1,6-glucan linked to an ?1,3-DD-heptan, and wherein the last DD-Hep residue of ?1,3-DD-heptan is capped with ?-GlcNAc residue. Compositions comprising the compound, uses of the compound, and antibodies raised against the compound are also described.Type: ApplicationFiled: July 30, 2010Publication date: June 28, 2012Inventors: Eleanora Altman, Blair A. Harrison, Vandana Chandan
-
Publication number: 20120165266Abstract: Disclosed are the novel glycolipoprotein gintonin isolated and identified from ginseng, a method for preparing the same, and uses thereof. Gintonin causes a transient increase in intracellular free Ca2+ level, which in turn activates endogenous Ca2+-activated chloride channel to elevate intracellular calcium levels. Therefore, the novel glycolipoproteins are useful in the therapy and prophylaxis of calcium deficiency-associated diseases as well as effectively inducing calcium-dependent physiological activities, including adaptogenic activity, immunostimulatory activity, aphrodisiac activity, neuroprotection and neuroactivation, angiogenesis, and antidiabetic activity.Type: ApplicationFiled: August 12, 2010Publication date: June 28, 2012Inventors: Seung Yeol Nah, Mi Kyung Pyo, Sun Hye Choi, Byung Hwan Lee, Tae Joon Shin
-
Publication number: 20120157390Abstract: Smac mimetics that inhibit IAPs.Type: ApplicationFiled: February 29, 2012Publication date: June 21, 2012Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. CONDON, Matthew G. LaPORTE, Yijun DENG, Susan R. RIPPIN
-
Publication number: 20120157391Abstract: The present invention was made in view of an object to produce a novel proteoglycan-containing material, and find a novel use and/or a superior effect of the proteoglycan-containing material. The present invention provides a proteoglycan-containing material obtained from fish cartilage, wherein the proteoglycan-containing material comprises an acidic saccharide component having a molecular weight of not less than 2000 kDa. The proteoglycan-containing material provides advantageous effects for skin-moisturizing and skin anti-aging, including a superior skin fibroblast proliferation effect, an effect of enhancing and improving the skin barrier function, an effect of enhancing and improving the skin's capability to produce collagen, a dermis-thickening inhibition effect, and the like.Type: ApplicationFiled: July 16, 2010Publication date: June 21, 2012Inventors: Masashi Goto, Kazushi Yamamoto, Youji Katou, Yohtaro Katagata, Seiko Itou
-
Publication number: 20120156254Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.Type: ApplicationFiled: December 16, 2011Publication date: June 21, 2012Applicant: BIOLAMINA ABInventors: KARL TRYGGVASON, SERGEY RODIN
-
Publication number: 20120148502Abstract: Tumors can be selectively targeted via compounds provided herein according to the formula, or a pharmaceutically acceptable salt thereof, wherein RA and RB are as defined herein. Tumors can be imaged or targeted for therapeutic treatment using compounds described herein where at least one RA or at least one RB group comprises a imaging agent, a therapeutic agent, or a member of a specific binding pair which can be associated with a secondary imaging agent, such as a microbubble for ultrasonic imaging.Type: ApplicationFiled: May 5, 2010Publication date: June 14, 2012Applicant: Arizona Board of Regents, a body corporate of the State of Ariz. acting for and on behalf of Ariz.Inventors: Sidney Hecht, Ryan Schmaltz, Krystal Tsosie
-
Publication number: 20120142610Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘IQ motif containing GTPase activating protein’ (IQGAP), in particular, by targeting natural antisense polynucleotides of ‘IQ motif containing GTPase activating protein’ (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP.Type: ApplicationFiled: August 25, 2010Publication date: June 7, 2012Applicant: OPKO CURNA, LLCInventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
-
Publication number: 20120135934Abstract: An object of the present invention is to enable the repair and regeneration of articular cartilage, which could not be achieved by conventional therapies, and to provide a safe and inexpensive agent that is effective for the treatment of joint diseases such as osteoarthritis. According to the present invention, a combined formulation for simultaneously, separately, or sequentially administering a hyaluronic acid and an animal mucin-type glycoprotein for the treatment of joint diseases is provided.Type: ApplicationFiled: January 29, 2010Publication date: May 31, 2012Applicants: RIKENInventors: Kiminori Ushida, Koji Kihira, Takayuki Baba, Kayoko Taniguchi, Makoto Urai, Masato Sato, Naoshi Ohta, Joji Mochida
-
Publication number: 20120134925Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.Type: ApplicationFiled: May 24, 2010Publication date: May 31, 2012Inventors: Benjamin Sullivan, Tannin Schmidt, Edward R. Truitt, Nicole Barbara Justis Truitt, David Sullivan
-
Publication number: 20120135941Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘C terminus of HSP70-Interacting Protein’ (CHIP), in particular, by targeting natural antisense polynucleotides of ‘C terminus of HSP70-Interacting Protein’ (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.Type: ApplicationFiled: August 20, 2010Publication date: May 31, 2012Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
-
Publication number: 20120129780Abstract: The present invention relates generally to the field of brain health, brain protection, maintenance of cognitive function, prevention of cognitive decline and cognitive disorders. Neuronal cells in the brain can be protected. Also cognitive performance can be increased.Type: ApplicationFiled: May 7, 2010Publication date: May 24, 2012Applicant: NESTEC S.A.Inventors: Bing Wang, Magali Faure, Jeroen Schmitt
-
Publication number: 20120121658Abstract: At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method.Type: ApplicationFiled: November 9, 2011Publication date: May 17, 2012Applicant: BIOTRONIK AGInventors: Alexander Borck, Matthias Gratz, Horst Kessler, Michael Joner, Florian Rechenmacher, Stefanie Neubauer
-
Publication number: 20120122801Abstract: The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a Duchenne Muscular Dystrophy (DMD) patient and the conjugate comprises an antisense oligonucleotide which causes ex on skipping and induces or restores the synthesis of dystrophin or variants thereof.Type: ApplicationFiled: January 12, 2012Publication date: May 17, 2012Applicant: Prosensa B.V.Inventor: Gerard Johannes PLATENBURG
-
Publication number: 20120122800Abstract: This invention provides a unique composition which includes a DNA dendrimer combined with siRNA molecule. Further, methods of preparing a composition which includes a DNA dendrimer combined with a siRNA molecule, methods of protecting a DNA dendrimer siRNA complex against degradation in body fluids, methods of protecting a DNA dendrimer against degradation in bodily fluids, and methods of delivering a DNA dendrimer into bodily fluids are provided.Type: ApplicationFiled: August 10, 2009Publication date: May 17, 2012Inventors: James Kadushin, Robert C. Getts
-
Publication number: 20120121659Abstract: At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method.Type: ApplicationFiled: November 9, 2011Publication date: May 17, 2012Applicant: BIOTRONIK AGInventors: Alexander Borck, Matthias Gratz, Horst Kessler, Michael Joner, Florian Rechenmacher, Stefanie Neubauer
-
Publication number: 20120114742Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L. MARTINEZ, Merry R. Sherman, Mark G.P. Saifer, L. David Williams
-
Publication number: 20120115795Abstract: The present invention relates to the ability of PLUNC proteins, such as SPLUNC1 and SPLUNC2, to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of PLUNC proteins to sodium channels.Type: ApplicationFiled: May 28, 2010Publication date: May 10, 2012Inventors: Robert Tarran, Monroe Jack Stutts, Scott Donaldson
-
Publication number: 20120114558Abstract: The present invention relates to aptamer/drug conjugate complexes and the use of such complexes, together with a trigger compound, to inducibly release a drug. Through these complexes, the present invention provides a means for establishing a drug reservoir in a subject, whereby drug may be released as needed. One specific embodiment of the invention provides an aptamer/insulin conjugate complex from which insulin may be released by an innocuous, orally administrable trigger, such as quinine.Type: ApplicationFiled: September 26, 2011Publication date: May 10, 2012Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Milan N. Stojanovic, Renjun Pei, Steven Michael Forna Taylor
-
STRUCTURAL AND MECHANISTIC BASIS FOR NOVEL COMPOUND BIOSYNTHESIS USING THE 4-ELECTRON HEXOSE OXIDASE
Publication number: 20120108498Abstract: A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections.Type: ApplicationFiled: October 1, 2010Publication date: May 3, 2012Applicant: Academia SinicaInventors: Tsung-Lin Li, Yu-Chen Liu, Yi-Shan Li, Syue-Yi Lyu -
Publication number: 20120107408Abstract: Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins and phospholipids, distributed in the matrix, and a three-phase emulsion process for their preparation.Type: ApplicationFiled: January 11, 2012Publication date: May 3, 2012Inventors: Michael Ausborn, Olivier Lambert, Oskar Nagele
-
Publication number: 20120107307Abstract: This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N?-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.Type: ApplicationFiled: March 23, 2010Publication date: May 3, 2012Applicant: ARDEA BIOSCIENCES INC.Inventors: Jean-Michel Vernier, Hong Woo Kim, Marion Hitchcock, Shunqi Yan
-
Publication number: 20120108504Abstract: Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, type II diabetes, appetite control after bariatric surgery, insulin resistance, lipodystrophy and hypothalamic amenorrhea, obesity-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance.Type: ApplicationFiled: June 25, 2010Publication date: May 3, 2012Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventor: Laszlo Otvos, JR.
-
Publication number: 20120101045Abstract: The disclosure provides fusion polypeptides and constructs useful in delivering anionically charged nucleic acid molecules including diagnostics and therapeutics to a cell or subject. The fusion constructs include a protein transduction domain and a nucleic acid binding domain, or a protein transduction domain and a nucleic acid that is coated with one or more nucleic acid binding domains sufficient to neutralize an anionic charge on the nucleic acid. Also provided are methods of treating disease and disorders such as cell proliferative disorders.Type: ApplicationFiled: May 7, 2010Publication date: April 26, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Steven F. Dowdy, Akiko Eguchi
-
Patent number: 8163875Abstract: The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.Type: GrantFiled: April 16, 2004Date of Patent: April 24, 2012Assignee: Biogen Idec MA Inc.Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Anthony Rossomando